Plain-English translation of NCT06249321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether mFOLFIRINOX—a combination of four chemotherapy drugs—works better when combined with radiation therapy for patients with advanced pancreatic cancer that did not respond to previous chemotherapy. The study focuses specifically on patients whose cancer markers (called CA19-9) are at normal levels, which may indicate their tumors respond better to this combination approach. Researchers will track how well the medication and radiation work together and monitor for side effects.
Pancreatic cancer is one of the hardest cancers to treat, and most patients are diagnosed at an advanced stage when surgery is not an option. Early research suggests that patients with normal CA19-9 levels may benefit more from combining chemotherapy with radiation therapy than from chemotherapy alone, but this approach needs to be tested in a formal clinical trial.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the chemotherapy medication intravenously every 2 weeks in cycles of 4 weeks. After about 2 to 6 cycles of chemotherapy, you will then receive radiation therapy to your pancreas area using advanced techniques that precisely target the tumor. Throughout the study, you will have regular blood tests and imaging scans every 4 weeks to measure how well the treatment is working and to watch for side effects. The trial is enrolling 30 patients total.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China